A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

205

Enrollment

INDUSTRY

Sponsor class

Stopped Study closed due to portfolio prioritization

Conditions

Small Cell Lung Cancer
Non-small Cell Lung Cancer, Squamous
Non-small Cell Lung Cancer, Non-squamous
Head and Neck Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma
Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Prostate Cancer
Melanoma

Interventions

DRUG: ladiratuzumab vedotin
DRUG: pembrolizumab

Sponsor

Seagen Inc.

Collaborators

[object Object]